Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Stomach Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Solid Tumors 1Sarcoma, Synovial 1Sarcoma 1Non-small Cell Lung Cancer Metastatic 1Neoplasms by Site 1Neoplasms 1Mesothelioma, Malignant 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Advanced Solid Tumor 1Adenocarcinoma Gastric 1Adenocarcinoma 1

Interventions

Injections 3pembrolizumab 2olaparib 2atezolizumab 2Leucovorin 2Irinotecan 2ulixertinib 1toripalimab 1tipifarnib 1sotorasib 1serabelisib 1mirdametinib 1famitinib 1camrelizumab 1adagrasib 1Taxes 1Ramucirumab 1Radiation 1Paclitaxel 1IFL protocol 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Fluorouracil 1Docetaxel 1Bevacizumab 1BID protein, human 1Appointments and Schedules 1Albumin-Bound Paclitaxel 1APG-1387 15-fluorouridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced Solid Tumor × Ramucirumab × Clear all
NCT04557384 2023-02-27

A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Terminated
3 enrolled 9 charts
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡